Sign in
CompletedPhase 2

Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes

Key facts

Who runs it
University of Maryland, Baltimore
Where
Baltimore, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
40 people enrolled
Started
9 Oct 2023
Ended
8 Aug 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Baseline surveys, Cognitive testing and EMAs
  • Actiwatch
  • suvorexant (or placebo)
  • Placebo
Record updated
30 October 2025

Who can take part

Age
60 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Meets Diagnostic and Statistical Manual - Fifth Edition (DSM-5) diagnostic criteria for insomnia disorder
  • Insomnia Severity Index total score >10
  • Insomnia symptoms must include problems with wake after sleep onset
  • Insomnia symptom duration > 6 months
  • Baseline self-reported total sleep time < 6.5 hours per night

Who cannot take part

  • History of previous allergic reaction, sensitivity, or severe side effects to sedative hypnotics
  • CYP3A inhibitors
  • High risk for untreated organic sleep disorders other than insomnia (narcolepsy, periodic limb movement disorder, etc) as determined by structured clinical interview and investigator clinical judgment
  • Current diagnosis of a major untreated psychiatric disorder(s)
  • History of serious suicide attempt within past 5 years
  • History of alcohol or substance abuse (including prescription medication abuse) within past 5 years
  • Heavy alcohol consumption (e.g., >5 drinks per day or > 14 drinks per week
  • Heavy caffeine use [(>2 cups of coffee/day (equivalent)
  • Current tobacco or nicotine use
  • Refusal to discontinue or intention to initiate OTC or other sleep aids during study period

Where in United States

  • University of Maryland, BaltimoreBaltimore, United States

About the trial

What the trial wants to find out

The goal of this study is to examine the impact of suvorexant, an FDA-approved insomnia medication, on daytime symptoms (as measured by the Daytime Insomnia Symptoms Scale: cognition, positive mood, negative mood, and fatigue/sleepiness) among older adults with insomnia. The primary hypothesis is that relative to placebo, suvorexant will improve sleep and daytime symptoms. The word "placebo" refers to a harmless pill with no therapeutic effect.

The 2 groups in the trial

  • TreatmentTreatment being tested

    Participants will start on 10mg suvorexant, po, qhs, including instructions on dosage, expectations, and potential side effects, for two nights. Following this low-dose run-in period, individuals in the treatment condition will be increased to 20mg for a 14-day active treatment period (i.e.,16 nights taking a pill). Other assessments include self-report research questionnaires and cognitive testing (completed at baseline and post-treatment), as well as EMA surveys, daily sleep diaries, and actigraphy.

    Treatment: Baseline surveys, Cognitive testing and EMAs, Actiwatch, and suvorexant (or placebo)

  • PlaceboPlacebo, for comparison

    Participants in the control condition will take placebo (no drug) pill form, po, qhs, including instructions on dosage, expectations, and potential side effects for (16 nights taking a pill). Other assessments include self-report research questionnaires and cognitive testing, daily sleep diaries, and actigraphy.

    Treatment: Baseline surveys, Cognitive testing and EMAs, Actiwatch, and Placebo

Results explained

A paper that names this trial, explained in plain words.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Impact of Suvorexant on Cognitive Function and Daytime Symptoms Among Community-dwelling Older Adults With Insomnia: A Placebo-controlled, Randomized Clinical Trial Using Remote Monitoring and Ecological Momentary Assessment
Publications
Record updated
30 October 2025